Sjøgren P, Banning A M, Henriksen H
Ugeskr Laeger. 1989 Jan 2;151(1):25-8.
A retrospective investigation was undertaken of 48 cancer patients receiving long-term treatment with high dosages of epidural opioids. Prior to introduction of the epidural catheter, the patients were in stable oral opioid treatment (median dose: 300 mg morphine/24 hours, range 40-1,360). The effect of stable epidural opioid treatment (median dose: 90 mg morphine/24 hours, range 16-600) in the first catheter was assessed as good in 20, reasonable in 14 and poor in 13. The effect could not be assessed in one patient. Twenty-nine patients could be assessed on pure and stable epidural opioid treatment. The effect was good in 14, reasonable in seven and poor in eight. If the patients were subdivided according to the type of pain, 16 had somatic and/or visceral types of pain while 13 had neurogenic pain. Epidural opioid treatment of neurogenic pain was found to produce statistically significantly poorer results than in the case of somatic/visceral pain (p less than 0.05). At the time of assessment, no statistically significant difference was present in the epidural opioid dosage between the groups. The patients were subdivided into a low dosage group and a high dosage group. The low dosage group comprised patients who had received oral opioid treatment with less than 300 mg morphine/24 hours and the high dosage group comprised patients who received equal or greater than 300 mg morphine/24 hours. Epidural opioid treatment was found to provide statistically significantly better results in the low dosage group (p less than 0.05). In this group, a tendency to better relief of neurogenic pain was observed as compared with the high dosage group. At the time of assessment, no statistically significant difference was present in the epidural opioid dosage between the high dosage and low dosage groups.(ABSTRACT TRUNCATED AT 250 WORDS)
对48例接受高剂量硬膜外阿片类药物长期治疗的癌症患者进行了回顾性调查。在置入硬膜外导管之前,患者接受稳定的口服阿片类药物治疗(中位剂量:300毫克吗啡/24小时,范围40 - 1360毫克)。首次导管置入时稳定的硬膜外阿片类药物治疗(中位剂量:90毫克吗啡/24小时,范围16 - 600毫克)效果评估为良好的有20例,尚可的有14例,差的有13例。1例患者效果无法评估。29例患者可评估单纯且稳定的硬膜外阿片类药物治疗效果。效果良好的有14例,尚可的有7例,差的有8例。若根据疼痛类型对患者进行细分,16例有躯体和/或内脏型疼痛,13例有神经源性疼痛。结果发现,硬膜外阿片类药物治疗神经源性疼痛的效果在统计学上显著低于躯体/内脏型疼痛(p < 0.05)。评估时,各亚组间硬膜外阿片类药物剂量无统计学显著差异。患者被分为低剂量组和高剂量组。低剂量组包括接受口服阿片类药物治疗剂量低于300毫克吗啡/24小时的患者,高剂量组包括接受剂量等于或高于300毫克吗啡/24小时的患者。结果发现,硬膜外阿片类药物治疗在低剂量组效果在统计学上显著更好(p < 0.05)。与高剂量组相比,该组神经源性疼痛缓解有更好的趋势。评估时,高剂量组和低剂量组间硬膜外阿片类药物剂量无统计学显著差异。(摘要截选至250词)